Relmada Therapeutics (RLMD) Competitors $0.61 +0.04 (+6.86%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$0.60 -0.01 (-2.01%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RLMD vs. CELU, IGMS, JMAC, MGX, ASRT, CABA, INMB, STRO, GNTA, and ARTVShould you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include Celularity (CELU), IGM Biosciences (IGMS), Maxpro Capital Acquisition (JMAC), Metagenomi (MGX), Assertio (ASRT), Cabaletta Bio (CABA), INmune Bio (INMB), Sutro Biopharma (STRO), Genenta Science (GNTA), and Artiva Biotherapeutics (ARTV). These companies are all part of the "pharmaceutical products" industry. Relmada Therapeutics vs. Its Competitors Celularity IGM Biosciences Maxpro Capital Acquisition Metagenomi Assertio Cabaletta Bio INmune Bio Sutro Biopharma Genenta Science Artiva Biotherapeutics Celularity (NASDAQ:CELU) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations. Does the media favor CELU or RLMD? In the previous week, Relmada Therapeutics had 3 more articles in the media than Celularity. MarketBeat recorded 5 mentions for Relmada Therapeutics and 2 mentions for Celularity. Celularity's average media sentiment score of 1.43 beat Relmada Therapeutics' score of -0.05 indicating that Celularity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celularity 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relmada Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer CELU or RLMD? Relmada Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 723.45%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relmada Therapeutics is more favorable than Celularity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Relmada Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has stronger earnings & valuation, CELU or RLMD? Celularity has higher revenue and earnings than Relmada Therapeutics. Celularity is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelularity$54.22M1.53-$57.89M-$2.65-1.31Relmada TherapeuticsN/AN/A-$79.98M-$2.22-0.27 Do insiders and institutionals have more ownership in CELU or RLMD? 19.0% of Celularity shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 22.1% of Celularity shares are held by insiders. Comparatively, 20.7% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, CELU or RLMD? Celularity has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Is CELU or RLMD more profitable? Relmada Therapeutics has a net margin of 0.00% compared to Celularity's net margin of -106.77%. Relmada Therapeutics' return on equity of -223.17% beat Celularity's return on equity.Company Net Margins Return on Equity Return on Assets Celularity-106.77% -271.88% -42.82% Relmada Therapeutics N/A -223.17%-180.41% SummaryRelmada Therapeutics beats Celularity on 9 of the 15 factors compared between the two stocks. Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLMD vs. The Competition Export to ExcelMetricRelmada TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.86M$2.48B$5.61B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-0.2722.0530.2725.74Price / SalesN/A742.42469.95115.79Price / CashN/A184.4138.2159.48Price / Book1.274.838.846.15Net Income-$79.98M$31.61M$3.25B$265.06M7 Day Performance3.37%4.55%3.71%2.60%1 Month Performance-3.92%5.69%5.85%2.83%1 Year Performance-76.37%12.71%30.25%25.58% Relmada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLMDRelmada Therapeutics4.5912 of 5 stars$0.61+6.9%$5.00+723.5%-76.4%$18.86MN/A-0.2710CELUCelularity0.4334 of 5 stars$3.23-0.3%N/A+17.3%$77.60M$54.22M-1.22220Positive NewsIGMSIGM Biosciences4.5462 of 5 stars$1.29+1.6%$5.50+326.4%-85.3%$76.57M$2.68M-1.43190JMACMaxpro Capital AcquisitionN/A$5.68+1.7%N/A+4,028.1%$76.20MN/A0.002,021MGXMetagenomi2.6211 of 5 stars$1.83-4.7%$13.00+610.4%-38.7%$71.77M$52.29M-0.87236News CoverageEarnings ReportAnalyst ForecastASRTAssertio2.5127 of 5 stars$0.73-0.5%$2.63+262.1%-23.5%$69.82M$124.96M-2.2720Earnings ReportAnalyst ForecastCABACabaletta Bio2.781 of 5 stars$1.33-2.2%$14.43+984.9%-62.3%$69.01MN/A-0.4950Gap DownINMBINmune Bio2.3747 of 5 stars$2.40-6.3%$18.40+666.7%-63.6%$68.06M$10K-0.9710STROSutro Biopharma4.2263 of 5 stars$0.77-3.7%$6.11+691.4%-78.3%$68.02M$62.04M-0.31240Analyst ForecastGNTAGenenta Science2.816 of 5 stars$3.54-4.7%$25.00+607.2%-23.8%$67.87MN/A0.007Positive NewsGap UpHigh Trading VolumeARTVArtiva Biotherapeutics2.7776 of 5 stars$2.56-7.2%$17.80+595.3%-76.4%$67.42M$250K0.0081 Related Companies and Tools Related Companies Celularity Alternatives IGM Biosciences Alternatives Maxpro Capital Acquisition Alternatives Metagenomi Alternatives Assertio Alternatives Cabaletta Bio Alternatives INmune Bio Alternatives Sutro Biopharma Alternatives Genenta Science Alternatives Artiva Biotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLMD) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access